Sarepta Therapeutics, Inc. · NASDAQ:SRPT

Sarepta Therapeutics — Q1 2026 Earnings Presentation

24 slides from Sarepta Therapeutics's earnings presentation, May 6, 2026

  1. Slide 1: First Quarter 2026 Financial Results

    Patients can’t wait for the next breakthrough in medical research. So neither will we. First Quarter 2026 Financial Results Wednesday, May 6, 2026 DILLON Living with Duchenne muscular dystrophy ©SAREPTA THERAPEUTICS, INC. 2026. ALL RIGHTS RESERVED. 1

  2. Slide 2: Forward-looking statements

    Forward-looking statements In order to provide Sarepta’s investors with an understanding of its current results and future prospects, forward-looking statements will be made during this presentation. Any statements that are not statements of historical fact may be deemed to be forward-looking statem

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures This presentation includes both GAAP information and Non-GAAP information. Non-GAAP net income (loss) is defined as GAAP net income (loss) excluding interest expense/income, net, depreciation and amortization expense, stock-based compensation expense, loss (gain) on strat

  4. Slide 4: Contents

    Contents Opening Remarks Doug Ingram 5-6 R&D Highlights Louise Rodino-Klapac, PhD 7 - 11 Commercial Performance Patrick Moss, PharmD 12 - 14 Financial Results Ryan Wong 15 - 18 ©SAREPTA THERAPEUTICS, INC. 2026. ALL RIGHTS RESERVED. 4

  5. Slide 5: 2026 Strategic Priorities

    2026 Strategic Priorities 1 2 3 Stabilize Maintain Advance and Drive Strong Potential Commercial Financial Best-in-Class Growth Position siRNA Pipeline ©SAREPTA THERAPEUTICS, INC. 2026. ALL RIGHTS RESERVED. 5

  6. Slide 6: Q1 2026 and Recent Highlights

    Q1 2026 and Recent Highlights Corporate Highlights R&D Updates Financial Results • First commercial sale of • Positive preliminary siRNA data in • Profitable and cash-flow positive ELEVIDYS in Japan by Chugai FSHD and DM1: Favorable safety and base business: GAAP and Non- Pharmaceuticals triggers $4

  7. Slide 7: R&D Updates

    R&D Updates Louise R. Rodino-Klapac, PhD President, R&D and Technical Operations ©SAREPTA THERAPEUTICS, INC. 2026. ALL RIGHTS RESERVED. 7

  8. Slide 8: Early Clinical Data Strengthen Potential Best-in-Class Approach for SRP-1001 and SRP-1003 to Treat FSHD1 and DM1

    Early Clinical Data Strengthen Potential Best-in-Class Approach for SRP-1001 and SRP-1003 to Treat FSHD1 and DM1 • Maximizing Therapeutic Delivery and Effect to Muscle – Clinical experience to date matches preclinical data: The TRiMTM platform’s αvβ6 integrin-targeting ligand drives potentially grea

  9. Slide 9: ENDEAVOR (Study SRP-9001-103) Cohort Advancing; Dosing Underway

    ENDEAVOR (Study SRP-9001-103) Cohort 8 Advancing; Dosing Underway • 6-Month study adding prophylactic sirolimus to standard immunosuppression in non-ambulatory population • Preliminary data expected by end of 2026 Up to 31 Days Part 2 Screening Baseline 12 Weeks Study 305 (out to 6 months) 60 Days N

  10. Slide 10: Regulatory Progress: AMONDYS and VYONDYS

    Regulatory Progress: AMONDYS 45 and VYONDYS 53 • Cleared by FDA to submit ESSENCE data and real- world evidence as part of the sNDAs • sNDAs successfully submitted to FDA at end of April 2026 ©SAREPTA THERAPEUTICS, INC. 2026. ALL RIGHTS RESERVED. 10

  11. Slide 11: Key Upcoming Milestones

    Key Upcoming Milestones GENE siRNA THERAPY ELEVIDYS SRP-1001 SRP-1005 Duchenne FSHD1 Huntington’s ENDEAVOR Cohort 8 complete MAD study data, disease primary endpoint data collection – incl. circulating biomarkers First patient in (FPI) 2H 2026 – 2H 2026 – 1H 2026 SRP-9003 Proof-of-biology data SRP-1

  12. Slide 12: Commercial Performance

    Commercial Performance Patrick E. Moss, PharmD Executive Vice President, Chief Commercial Officer ©SAREPTA THERAPEUTICS, INC. 2026. ALL RIGHTS RESERVED. 12

  13. Slide 13: Q1 Performance and Outlook for ELEVIDYS

    Q1 Performance and Outlook for ELEVIDYS Q1 2026 Performance • ELEVIDYS performance reflected expectations: $ in Millions – Measured demand influenced by treatment-journey lead times, patient decision cycles and continued rebuilding of confidence • PMOs continue to deliver durable performance: – Seas

  14. Slide 14: Executing Commercial and Educational Initiatives

    Executing Commercial and Educational Initiatives Expanding Field Deepening Reach Leading with Enhancing Patient Resources at Sites of Care Science & Data & Caregiver • Expanded our field sales • Rebalance the ELEVIDYS • Reinforcing favorable Education force to drive ELEVIDYS narrative to more benefi

  15. Slide 15: Financial Results

    Financial Results Ryan H. Wong Executive Vice President, Chief Financial Officer ©SAREPTA THERAPEUTICS, INC. 2026. ALL RIGHTS RESERVED. 15

  16. Slide 16: Financial Highlights

    Financial Highlights Q1 2026 Financial Results Operating Income Cash and Product Revenue Total Revenues GAAP / Non-GAAP1 Investments2 $331 million $731 million $358 / $398 million $748 million Profitable Foundation to Support Long-Term Growth • Base business remains profitable: GAAP and Non-GAAP ope

  17. Slide 17: Q1 2026 Select Financial Data

    Q1 2026 Select Financial Data Q1 Q1 YoY $ In Millions, except percentages 2026 2025 % Total Product Revenues $331 $612 -46% Collaboration and Other Revenues $400 $133 Total Revenues $731 $745 -2% Cost of Sales (excludes amortization of in-licensed rights) $109 $138 -21% Combined GAAP R&D and SG&A Ex

  18. Slide 18: FY 2026 Guidance

    FY 2026 Guidance Unchanged from February 25, 2026 FY 2026 Guidance Assumptions As of May 6, 2026 • PMO revenue expected to see modest decline year over year from ELEVIDYS cannibalization Total Net Product Revenues $1,200-1,400M • Range of ELEVIDYS revenues dependent on impact and timing of commercia

  19. Slide 19: Q&A

    Q&A ©SAREPTA THERAPEUTICS, INC. 2026. ALL RIGHTS RESERVED. 19

  20. Slide 20: Appendix

    Appendix ©SAREPTA THERAPEUTICS, INC. 2026. ALL RIGHTS RESERVED. 20

  21. Slide 21: Condensed Consolidated Statements of Income (Loss)

    Condensed Consolidated Statements of Income (Loss) $ in Thousands, except per share amounts Note: Tables may not foot due to rounding ©SAREPTA THERAPEUTICS, INC. 2026. ALL RIGHTS RESERVED. 21

  22. Slide 22: Reconciliation of GAAP Reported Net Income to Non-GAAP Net Income

    Reconciliation of GAAP Reported Net Income to Non-GAAP Net Income $ in Thousands, except per share amounts Note: Tables may not foot due to rounding ©SAREPTA THERAPEUTICS, INC. 2026. ALL RIGHTS RESERVED. 22

  23. Slide 23: Reconciliation of GAAP to Non-GAAP Reported Total Effective Tax Rate, Operating Income, and SG&A and R&D Expenses

    Reconciliation of GAAP to Non-GAAP Reported Total Effective Tax Rate, Operating Income, and SG&A and R&D Expenses $ in Thousands, except per share amounts Note: Tables may not foot due to rounding ©SAREPTA THERAPEUTICS, INC. 2026. ALL RIGHTS RESERVED. 23

  24. Slide 24: PMO Revenue Breakdown by Product

    PMO Revenue Breakdown by Product $ in Thousands ©SAREPTA THERAPEUTICS, INC. 2026. ALL RIGHTS RESERVED. 24

Sarepta Therapeutics — Q1 2026 Earnings Presentation on 6ix